Department of Medical Oncology, Istituti Ospitalieri of Cremona, Italy.
Lung Cancer. 2013 Apr;80(1):106-8. doi: 10.1016/j.lungcan.2013.01.003. Epub 2013 Feb 1.
Thymic carcinoma (TC) is a rare intrathoracic malignancy that it can be invasive and refractory to conventional treatment. Comprehensive genomic analysis evidenced a molecularly distinct subset of thymic carcinoma with high prevalence of c-kit mutation, which may behave as a gastrointestinal stromal tumor (GIST). Here, we present a case report of TC with c-Kit mutation, who has relapsed after exposure to multiple lines of combination chemotherapy, but he has shown an impressive and long lasting response to sunitinib after imatinib failure.
胸腺癌(TC)是一种罕见的胸腔内恶性肿瘤,具有侵袭性和对常规治疗的抵抗性。全面的基因组分析证实了胸腺癌的一个分子上不同的亚组,其 c-kit 突变的患病率很高,可能表现为胃肠道间质瘤(GIST)。在这里,我们报告了一例 c-Kit 突变的 TC 病例,该患者在接受多种联合化疗方案治疗后复发,但在伊马替尼治疗失败后,舒尼替尼治疗取得了令人印象深刻且持久的反应。